Evidence map›Paper›PMID 25882839›Full record

ArticleThe Journal of biological chemistry2015

A Point Mutation in the Ubiquitin Ligase RNF170 That Causes Autosomal Dominant Sensory Ataxia Destabilizes the Protein and Impairs Inositol 1,4,5-Trisphosphate Receptor-mediated Ca2+ Signaling.

Forrest A Wright, Justine P Lu, Danielle A Sliter, Nicolas Dupré, Guy A Rouleau, Richard J H Wojcikiewicz

Open access · hybridAbstract read
In one paragraph

Article in The Journal of biological chemistry, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
2.0field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 39 citations in OpenAlex.

  1. Article
  2. Article
  3. Canine RNF170 Single Base Deletion in a Naturally Occurring Model for Human Neuroaxonal Dystrophy.Movement disorders : official journal of the Movement Disorder Society · 2024
    Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Article
  9. Review
  10. Mutation inJournal of neurology, neurosurgery, and psychiatry · 2020
    Article
  11. The emerging link between IPCell calcium · 2020
    Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Tumor suppressive CaCell stress · 2017
    Article
  17. Review
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 2 countries.

Forrest A WrightFrom the Department of Pharmacology, SUNY Upstate Medical University, Syracuse, New York 13210.
Justine P LuFrom the Department of Pharmacology, SUNY Upstate Medical University, Syracuse, New York 13210.
Danielle A Sliterthe NINDS, National Institutes of Health, Bethesda, Maryland 20892.
Nicolas Dupréthe Neuromuscular and Neurogenetic Disease Clinic, CHU de Québec, Laval University, Quebec City, Quebec G1J 1Z4, Canada, and.
Guy A Rouleauthe Montreal Neurological Institute and Hospital and Department of Neurology and Neurosurgery, McGill University, Montreal, Quebec H3A 2B4, Canada.
Richard J H WojcikiewiczFrom the Department of Pharmacology, SUNY Upstate Medical University, Syracuse, New York 13210, wojcikir@upstate.edu.
SUNY Upstate Medical University · USMontreal Neurological Institute and Hospital · CANational Institutes of Health · US

Funding

IP3 Receptor Ubiquitination and Down-regulationR01DK049194 · NIDDK · UPSTATE MEDICAL UNIVERSITY · PI WOJCIKIEWICZ, RICHARD J H · 2000 to 2012
$3.7M
DOWN-REGULATION OF INSP3 RECEPTORSR29DK049194 · NIDDK · UPSTATE MEDICAL UNIVERSITY · PI WOJCIKIEWICZ, RICHARD J H · 1995 to 1999
–
NIDDK NIH HHS DK049194NIDDK NIH HHS R01 DK049194NIDDK NIH HHS R29 DK049194
6 · The paper itself

Abstract

RNF170 is an endoplasmic reticulum membrane ubiquitin ligase that contributes to the ubiquitination of activated inositol 1,4,5-trisphosphate (IP3) receptors, and also, when point mutated (arginine to cysteine at position 199), causes autosomal dominant sensory ataxia (ADSA), a disease characterized by neurodegeneration in the posterior columns of the spinal cord. Here we demonstrate that this point mutation inhibits RNF170 expression and signaling via IP3 receptors. Inhibited expression of mutant RNF170 was seen in cells expressing exogenous RNF170 constructs and in ADSA lymphoblasts, and appears to result from enhanced RNF170 autoubiquitination and proteasomal degradation. The basis for these effects was probed via additional point mutations, revealing that ionic interactions between charged residues in the transmembrane domains of RNF170 are required for protein stability. In ADSA lymphoblasts, platelet-activating factor-induced Ca(2+) mobilization was significantly impaired, whereas neither Ca(2+) store content, IP3 receptor levels, nor IP3 production were altered, indicative of a functional defect at the IP3 receptor locus, which may be the cause of neurodegeneration. CRISPR/Cas9-mediated genetic deletion of RNF170 showed that RNF170 mediates the addition of all of the ubiquitin conjugates known to become attached to activated IP3 receptors (monoubiquitin and Lys(48)- and Lys(63)-linked ubiquitin chains), and that wild-type and mutant RNF170 have apparently identical ubiquitin ligase activities toward IP3 receptors. Thus, the Ca(2+) mobilization defect seen in ADSA lymphoblasts is apparently not due to aberrant IP3 receptor ubiquitination. Rather, the defect likely reflects abnormal ubiquitination of other substrates, or adaptation to the chronic reduction in RNF170 levels.

Indexed as

Calcium SignalingPoint MutationAnimalsArginineAtaxiaCalciumCell LineCell MembraneEndoplasmic ReticulumExonsHeLa CellsHumansInositol 1,4,5-Trisphosphate ReceptorsLysineMiceMutationArginineCalciumInositol 1,4,5-Trisphosphate ReceptorsLysineProteasome Endopeptidase ComplexRNF170 protein, humanRNF170 protein, mouseUbiquitinUbiquitin-Protein Ligasescalcium intracellular releaseE3 ubiquitin ligaseendoplasmic reticulum (ER)inositol trisphosphate receptor (InsP3R)neurodegenerative diseaseRNF170

Identifiers

PMID25882839
PMCPMC4447968
OpenAlexW2014121269

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.